Merck (MRK) looks undervalued amid 2028 Keytruda patent fears—strong Q3 results, pipeline wins, and 12x P/E suggest upside.

Merck stock earns a cautious "Buy." Learn more about its valuation, Keytruda risks, pipeline potential, and long-term growth.

ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100) The combination demonstrated a ...

As has been the case for the past several years, industry experts will be focused on Merck at the 44 th Annual JP Morgan ...

ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100)The combination demonstrated a favorab ...

Merck MRK is expected to face some notable headwinds over the next few years that could affect its long-term growth outlook, the most significant being the upcoming loss of exclusivity (“LOE”) for its ...

On December 17, the US Food and Drug Administration moved to fast-track reviews of two experimental Merck & Co., Inc.

Pfizer's Eliquis, a blood thinner and one of its best-selling therapies, will lose patent exclusivity within the next few ...

Pfizer ( PFE +0.24%) pays a dividend that yields around 6.8%. While the yield has been pushed higher as share prices have ...

Pharma giant Merck & Co., Inc. (NYSE:MRK)’s shares are up by 1.9% year-to-date on the back of a strong run since early ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase ...

Bristol Myers Squibb's growth drugs rose 17% in the first nine months of 2025, helping offset a 16% legacy drug sales decline ...